Approach of Persisters Relapse in a Smear-negative Leprosy after Second MB-MDT Completion: An Arduous Case Report

Felix Hartanto; Astindari Astindari; Bagus Haryo Kusumaputra; Medhi Denisa Alinda; Muhammad Yulianto Listawan; Cita Rosita Sigit Prakoeswa; Dinar Adriaty

doi:10.3889/oamjms.2022.10309

Authors

Felix Hartanto Department of Dermatology and Venereology, Faculty of Medicine, Airlangga University, Dr. Soetomo General Academic Hospital, Surabaya, Indonesia
Astindari Astindari Department of Dermatology and Venereology, Faculty of Medicine, Airlangga University, Dr. Soetomo General Academic Hospital, Surabaya, Indonesia
Bagus Haryo Kusumaputra Department of Dermatology and Venereology, Faculty of Medicine, Airlangga University, Dr. Soetomo General Academic Hospital, Surabaya, Indonesia
Medhi Denisa Alinda Department of Dermatology and Venereology, Faculty of Medicine, Airlangga University, Dr. Soetomo General Academic Hospital, Surabaya, Indonesia
Muhammad Yulianto Listawan Department of Dermatology and Venereology, Faculty of Medicine, Airlangga University, Dr. Soetomo General Academic Hospital, Surabaya, Indonesia
Cita Rosita Sigit Prakoeswa Department of Dermatology and Venereology, Faculty of Medicine, Airlangga University, Dr. Soetomo General Academic Hospital, Surabaya, Indonesia
Dinar Adriaty Leprosy Study Group, Institute of Tropical Disease, Universitas Airlangga, Surabaya, Indonesia

DOI:

https://doi.org/10.3889/oamjms.2022.10309

Keywords:

Leprosy, Persisters bacilli, Relapse, Drug resistance

Abstract

Introduction: Many infectious disease intervention programs, including leprosy, are cautious about the establishment of relapse and drug resistance. This case report reports on a male patient who has had two relapses and had undergone twice MB-MDT treatment as well.

Case Report: A 31 year-old male, came with the main complaint of new hypopigmented patches appeared on the body since 4 months ago, which arose from his second MB-MDT treatment. He started his first MB-MDT treatment in 2019 and second MD-MDT in 2020. Slit skin smear yielded negative results and histopathological examination showed no signs of leprosy. Serological anti-PGL-1 antibody tests yielded very high IgM (3.163) and normal IgG (2) levels. PCR amplification examination showed positive, but DNA sequencing targeting rpoB, folP, and gyrA genes showed no mutations. He was diagnosed with persisters relapse in a borderline-lepromatous leprosy and was treated with rifampicin 600 mg/day for 2 weeks; combination of minocycline 100 mg/ day, clarithromycin 500 mg/ day, and clofazimine 50 mg/ day for 6 months; and methylprednisolone 32 mg/ day for the neuritis. No new lesions appeared during current treatment and he is also showing gradual improvement of foot drop in his left leg.

Discussion: The fact of a very high IgM levels after 2 courses of MB-MDT indicated that there is still bacteria that continued to induce antibody formation, thus supporting the persisters bacilli hypothesis in this case. Positive results of PCR amplification conclude that there is still M. leprae bacilli in skin tissues, which may be hidden in deeper tissues. We have to make a more proactive approach considering this was his second times of relapse, and knowing the fact that MB-MDT was consumed religiously in the two previous treatment.

Conclusion: In an arduous case like this, proactive step must be taken. Whenever possible, the use of whole genome sequencing is strongly advised.

Keywords: leprosy, persisters bacilli, relapse, drug resistance

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Plum Analytics Artifact Widget Block

References

Barua S. Global leprosy situation: Historical perspective, achievements, challenges and future steps. In: IAL Textbook of Leprosy. Genava: World Health Organization; 2017. p. 45-58. DOI: https://doi.org/10.5005/jp/books/12958_4

Irawan Y, Menaldi SL, Sjamsoe-Daili ES, Marissa M, Zoulba E. Suspected resistance of MDT-MB in multibacillary leprosy of hansen’s disease: Two case reports. J Gen Dermatol Venereol Indones. 2016;1(3):99-103. DOI: https://doi.org/10.19100/jdvi.v1i3.23

World Health Organization. Guidelines for Global Surveillance of Drug Resistance in Leprosy. Geneva: World Health Organization; 2009. p. 33. Available from: https://www.leprosyila.org/site/view/drug_resistance_guidelines2009_2.pdf [Last accessed on 2022 Apr 18].

Kaimal S, Thappa DM. Relapse in leprosy. Indian J Dermatol Venereol Leprol. 2009;75(2):126-35. https://doi/org/10.4103/0378-6323.48656 PMid:19293498 DOI: https://doi.org/10.4103/0378-6323.48656

Abbas AK, Lichtman AH, Pillai S. Humoral immune responses. In: Basic Immunology. 6th ed. Amsterdam, Netherlands: Elsevier; 1997. p. 137-57. Available from: https://publication/uuid/0AD0CBAD-3542-40E4-82D4-1AC98703A95F

Lavania M, Singh I, Turankar RP, Ahuja M, Pathak V, Sengupta U, et al. Molecular detection of multidrug-resistant Mycobacterium leprae from Indian leprosy patients. J Glob Antimicrob Resist. 2018;12:214-9. https://doi.org/10.1016/j.jgar.2017.10.010 PMid:29097343 DOI: https://doi.org/10.1016/j.jgar.2017.10.010

Narang T, Bishnoi A, Thakur V, Chatterjee D, Razmi TM, Kamat D, et al. Persistent plaques after release from treatment in slit-skin smear negative leprosy patients: Wait and watch or adopt a proactive approach? Dermatol Ther. 2020;33(6):e14226. https://doi.org/10.1111/dth.14226 PMid:32852123 DOI: https://doi.org/10.1111/dth.14226

Kamat D, Narang T, Ahuja M, Lavania M, Dogra S. Case report: Multidrug-resistant Mycobacterium leprae in a case of smearnegative relapse. Am J Trop Med Hyg. 2020;102(4):724-7. https://doi.org/10.4269/ajtmh.19-0905 PMid:32043454 DOI: https://doi.org/10.4269/ajtmh.19-0905